REDWOOD CITY, Calif., Feb. 11, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Barry Selick, chief executive officer of Threshold, will present at the BIO CEO & Investor Conference on Wednesday, February 13, 2008 at 2:00 p.m. ET. Dr. Selick will provide a general update on the Company including its Hypoxia-Activated Prodrug, TH-302, for the potential treatment of solid tumors.
